An interventional study of ELRA endoluminal radiofrequency ablation electrode (Taewoong, Seoul, Korea) in Hilar Cholangiocarcinoma and Biliary Obstruction, sponsored by Rajavithi Hospital. Completed at 1 site in Thailand. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2022-03-23.
Sponsored by Rajavithi Hospital · Not applicable, Interventional, and Treatment
The study aim to evaluate the efficacy of intraductal radiofrequency ablation for unresetable hilar cholangiocarcinoma in addition to biliary stenting. The patient would be randomized into 1:1 ratio of conventional group who received biliary stenting alone, and RFA group who receive intraductal RFA before biliary stenting. Immediate complications as well as long term stent patency and patient survival would be studied.
Study design: randomized single-blind control trial Study population: patient with unresectable hilar cholangiocarcinoma with obstructive jaundice who need hilar biliary stenting Primary endpoint: Biliary stent patency time Secondary endpoint: Patient survival Intervention
82 studies on the registry are indexed under Klatskin Tumor; 27 are open to participants now.
This study's enrollment of 70 is above the median of 55 across 56 interventional studies indexed under Klatskin Tumor.
Browse Klatskin Tumor studies →Rajavithi Hospital is the lead sponsor of 46 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patient receive endoscopic placement of metallic biliary stent for obstructive jaundice
Patient receive endoscopic intraductal radiofrequency ablation before placement of biliary stent for obstructive jaundice
Device: ELRA endoluminal radiofrequency ablation electrode (Taewoong, Seoul, Korea)
Intraductal radiofrequency ablation using ELRA endoluminal radiofrequency ablation electrode (Taewoong, Seoul, Korea) 10W 2 minutes at the obstructed bile duct before placing uncover self-expandable biliary metal stent
Biliary stent patency
The duration between primary intervention and first recurrent increased in serum total bilirubin after intervention up to 6 months after the primary procedure
Time frame: up to 6 months
Patient survival
Survival time after primary intervention and documented patient death at 6 months after primary intervention
Time frame: up to 6 months
This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Rajavithi Hospital